BACKGROUND:

 Rifampicin induces UGT1A1, an enzyme involved in raltegravir elimination, thereby potentially lowering raltegravir exposure. We examined the pharmacokinetics of raltegravir in HIV-infected patients on rifampicin-based antitubercular therapy in the ANRS 12 180 Reflate TB trial.

METHODS:

 Patients started raltegravir in combination with TDF and 3TC after initiation of rifampicin (10 mg/kg/d). In arm 1 (n=21) they received 400 mg BID raltegravir, while in arm 2 (n=16) they received 800 mg BID raltegravir initially then 400 mg BID four weeks after rifampicin discontinuation. Pharmacokinetic sampling was performed over 12-hour periods, 4 weeks after initiation of raltegravir together with rifampicin (period 1), 4 weeks after rifampicin discontinuation (period 2), and after the raltegravir dose reduction in arm 2 (period 3).

 

(후략)